Positive outcome no more likely in industry-funded trials

Positive outcome no more likely in industry-funded trials
Industry-sponsored clinical trials of rheumatoid arthritis drugs are no more likely to report positive outcomes than trials funded by other means, and in many cases use better methodology, according to research published in the July issue of Arthritis & Rheumatism.

(HealthDay) -- Industry-sponsored clinical trials of rheumatoid arthritis drugs are no more likely to report positive outcomes than trials funded by other means, and in many cases use better methodology, according to research published in the July issue of Arthritis & Rheumatism.

Nasim A. Khan, M.D., from the University of Arkansas for Medical Sciences in Little Rock, and colleagues reviewed 103 randomized controlled trials (RCTs) for rheumatoid drugs to examine whether industry funding was associated with outcomes.

The researchers found that 56.3 percent of RCTs were funded by industry, 18.4 percent were funded through nonprofit sources, 5.8 percent had mixed funding, and the funding source was not specified in the remaining 19.4 percent. In the 86 trials examined for outcomes there was no correlation between industry funding and positive outcomes (75.5 percent for industry versus 68.8 percent for non-industry, 40 percent for mixed, and 81.2 percent for unspecified). Industry-funded studies were more likely not to be published (P = 0.093) but were more likely to be double-blinded, adequately describe participant flow, and perform an intent-to-treat analysis.

"Industry funding was not associated with a higher likelihood of positive outcomes of published RCTs of drug therapy for , and industry-funded RCTs performed significantly better than non-industry-funded RCTs in terms of reporting the use of some key methodologic quality measures," Khan and colleagues conclude.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

Long-term NSAID use beneficial in knee osteoarthritis

date Mar 12, 2015

(HealthDay)—For patients with knee osteoarthritis, long-term nonsteroidal anti-inflammatory drug (NSAID) use is associated with improvements in symptoms and disease progression, according to a study published ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Gys
Jul 06, 2012
I just downloaded the full text of this article and there is no statement about the conflict of interest for the authors. Which makes me laugh.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.